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1. Introduction
   Pain can be difficult to treat, especially chronic pain. Fibromyalgia, 
neuropathic pain and chronic back pain are routinely treated 
with oral opioids, such as hydrocodone and oxycodone. A recent 
systematic review found no convincing evidence that oxycodone is 
of value in pain treatment from fibromyalgia, diabetic neuropathy, 
postherpetic neuralgia or neuropathic pain[1]. Osteoarthritis pain is 
frequently treated with oral nonsteroidal anti-inflammatory drugs 
(NSAIDs). When the NSAIDs are inadequate for pain control in 
osteoarthritis or rheumatoid arthritis, stronger agents are used such 
as corticosteroids, hydroxychloroquine, sulfasalazine, leflunomide, 
auranofin, etanercept, infliximab, anakinra and methotrexate. This is 
called the Carpenter approach[2]. If the hammer does not work, get 
a bigger hammer. All of these agents have serious adverse effects. 
Methotrexate can kill patients if an excessive dose is used.
   Of course, NSAIDs were discovered based on the structure of 
aspirin, a monoterpenoid, which comes from meadowsweet, 
Filipendula ulmaria. Opioids are alkaloids that come from the 
opium poppy, Papaver somniferum. The problem with these agents 
is that large doses are taken orally or by injection, travel throughout 
the body and have toxic effects where they are not needed. NSAIDs 
are used in chronic pain conditions, but are not effective for most 
patients[3]. NSAIDs cause 100 000 ulcers in the USA every year 
according to the Centers for Disease Control. Of these, 10 000 
patients die. NSAIDs also damage the kidneys and have other 
adverse effects. Opioids cause seizures and respiratory depression. 
They cause 14 000 deaths every year in the USA according to 
the Centers for Disease Control. They also cause addiction and 
tolerance such that after a couple of weeks, patients have to increase 
the dose to get any pain relief.
   This review will point out that there is a better way to treat pain 
than by giving large oral doses or injections to treat pain in the brain 
and brain stem. Liniments and other topical preparations can be 
used that are applied in small amounts to the skin where they are 
needed. Analgesic molecules in the preparations penetrate the skin 
in small but sufficient amounts, act where they are needed and are 
rapidly cleared from the skin and the body. 
2. What is the pain cycle
   There is a pain cycle in the body that starts with pain receptors on 
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sensory afferent neurons of the skin. These are small unmyelinated 
(C-type) or thinly myelinated (A delta-type) nerves. The sensory 
afferents have a pseudo-unipolar morphology[4]. A common 
axonal stalk sends axons to the skin and to the brain stem where 
they synapse with ascending neurons that communicate with the 
hippocampus, hypothalamus and other brain regions. This pseudo-
unipolar morphology may be important in reflex amplification of the 
pain cycle. The brain neurons communicate with descending neurons 
that synapse with neurons in the brain stem. These descending 
brain stem neurons have terminals in the skin that are neurotrophin 
secreting[5]. Activation of the pain cycle can magnify pain in the 
body.
   Sensory afferent neurons contain a number of different pain 
receptors. These pain receptors are activated or inhibited by various 
natural substances such as histamine that are made in the skin, work 
in the skin, and do not persist for very long in the skin. 
  These neurons are also regulated by input from the brain stem and 
the brain. The most abundant pain receptors in the skin are located 
on sensory afferent neurons and are called transient receptor potential 
(TRP) cation channels. These channels are usually made up of six 
membrane spanning units and a central cation permeable channel. 
Some TRP channels are also located in the brain and the brain stem. 
These receptors form a family of receptors that respond to heat, 
cold, mechanical stress and other painful stimuli. TRP channels have 
a characteristic of opening in response to an agonist, which then 
results in inhibition. In other words, agonists and antagonists can 
have the same long term effects, pain inhibition. TRP channels are 
not all expressed in the same skin afferent neurons. There are distinct 
neuronal populations that express the various TRP channels[4]. It is 
convenient to describe these receptors in terms of the agonists and 
antagonists that interact with them.
   The canonical TRP subfamily TRPC, has at least 7 members[6], 
which tend to be activated by diacylglycerol. Phospholipase C makes 
diacylglycerol, which is an endogenous compound.
   The vanilloid subfamily, TRPV, has 6 members and tends to be 
activated by heat[6]. However, TRPV4 can be activated by swelling 
caused by 5’,6’-epoxyeicosatetrienoic acid, an endogenous 
compound. Capsaicin is an agonist for TRPV1. Activation of the 
channel by capsaicin causes pain, results in later inactivation of the 
channel and relief of pain. Eugenol and gingerol are monoterpenoid 
agonists for TRPV1[7]. This channel is activated by endovanilloids, 
cannabinoids, endocannabinoids, hydroperoxyeicosatetraenoic 
acid (HPETE), hydroxyeicosatetraenoic acid (HETE) and other 
compounds[6]. Endovanilloids, endocannabinoids, HPETE and 
HETE are made in the skin, act in the skin and are quickly cleared 
from the skin. Bradykinin and ATP sensitize TRPV1 by stimulating 
protein kinase Cε dependent phosphorylation to greatly increase 
pain[8]. Lidocaine activates TRPV1, whereas isoflurane, enflurane, 
sevoflurane and desflurane sensitize TRPV1 can increase pain[7]. 
Dynorphins and adenosine are TRPV1 antagonists in the brain[7]. 
Histamine and several prostaglandins potentiate the activity of 
TRPV1, greatly increasing pain and itch[9]. TRPV2 is activated, 
then inhibited, by cannabidiol and tetrahydrocannabinol[7]. The 
monoterpenoid, citral, inhibits TRPV2[7]. TRPV3 is activated by 
camphor, thymol, eugenol, carveol, carvacrol, borneol, menthol, 
and all plant-derived monoterpenoids[6,10]. TRPV4 is activated by 
endocannabinoids, arachidonic acid metabolites, the diterpenoid 
bisandrographolide A, and is inhibited by the monoterpenoid 
citral[7]. TRPV5 and TRPV6 are less well characterized. TRPV5 can 
be inhibited by econazole[7].
   The melastatin subfamily, TRPM, has several members[6]. TRPM1 
is activated by steroids[9]. The TRPM2 receptor is activated by 
ADP-ribose, cyclic ADP-ribose, hydrogen peroxide and heat[6]. 
The TRPM3 receptor is activated by sphingosine. TRPM4 and 5 are 
activated by heat. TRPM8 is activated by cold, menthol and icilin. 
ADP-ribose, cyclic ADP-ribose, hydrogen peroxide and sphingosine 
are endogenous compounds that are made in the skin, act in the skin 
and can be quickly cleared from the skin.
   The ankyrin subfamily, TRPA, has one member. TRPA1 responds 
to allicin, isothiocyanates, cannabinoids, cinnamaldehyde and 
arachidonic acid[6]. Arachidonic acid is an endogenous compound 
that is made in the skin, acts in the skin and is quickly cleared 
from the skin. The A and J series of prostaglandins activate the 
channel[9]. TRPA1 also responds to methyl salicylate, isoflurane and 
lidocaine[4,7]. 
   The polycystin subfamily, TRPP, has three members[6]. They 
tend to respond to mechanical stress and calcium. The mucolipin 
subfamily TRPML has three members[6]. This family is not well 
characterized, appears to be located on lysosomal membranes and 
may respond to protons.
   All TRP channels are calcium channels[6]. Some are permeable to 
other cations as well such as Na+ and Mg2+. If TRP channels open 
too much, excessive calcium may enter the sensory nerve terminal 
and activate apoptosis mechanisms[11]. This apoptosis is an essential 
component of pain control. The nearby nerve growth factor secreting 
efferent terminals may facilitate the recovery of the apoptotic 
afferent terminals.
   Cannabinoids and endocannabinoids interact with cannabinoid 
receptors (CB) CB1 and CB2 to induce peripheral and central pain 
sensitization[12]. The endocannabinoids are endogenous, made 
locally, act locally and have short half lives. These compounds 
include 2-arachidonyl glycerol and anandamide. They also act on 
TRP channels as discussed above.
   Lipoxins are endogenous compounds made from arachidonic acid 
and interact with ALX receptors (ALX/formyl peptide receptor 2, 
lipoxin A4 receptor, resolvin D1 receptor) to cause pain. They are 
made locally, act quickly and do not persist in the skin. Lipoxins 
exist in a balance with resolvins, which are also made from 
arachidonic acid and relieve pain[13]. Resolvins interact with a 
number of receptors including ALX, GPR32 (G protein coupled 
receptor 32, resolvin D1 receptor, lipoxin A4 receptor), ChemR23 
(CMKLR1, chemokine like receptor 1, resolvin E1 receptor) and 
leukotriene B(4) receptor (BLT1). Resolvins also inhibit TRPA1, 
TRPV3 and TRPV4 to stop the pain cycle[14]. 
   Opioid receptors are involved in processing pain centrally. The 
µ,δδ, κ and nociceptin receptors are important in pain control, 
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tolerance and addiction[15]. Current therapy with oral opioids targets 
brain and spinal cord receptors. However, µ,δδ and κ receptors are 
also found on peripheral sensory neurons. The brain and spinal 
cord receptors bind to endogenous opioid peptides such as the 
endorphins, enkephalins, dynorphins and nociceptin. These peptides 
are produced in a balance in the brain to control pain. However, 
administration of large doses of oral opioids throws off this balance. 
Whereas enkephalins and endorphins usually cause analgesia, 
dynorphins and nociceptin can cause pain sometimes. Chronic use 
of oral opioids can cause an increase in pain, opioid hyperalgesia. 
As some opioid receptors become tolerant to agonist actions, other 
opioid receptors may have breaks in tolerance. Nociceptin may be 
involved in opioid hyperalgesia[16].
   There are many other receptors involved in the pain cycle: 
bradykinin receptors B1 and B2, serotonin (5-HT) receptors 5-HT1B 
and 5-HT3, ATP receptors P2X3 and P2X4, N-type calcium channels, 
voltage gated sodium channels, glutamatergic receptors and others[8]. 
Prostaglandin E receptors (EP) EP1, EP2, EP3C and EP4 also cause 
pain in the pain cycle[17]. Some of these receptors can be induced 
to augment the pain cycle. The B1 receptor is induced by tissue 
damage, tumor necrosis factor ααand interleukin-1β. Prostaglandins 
act on dorsal horn neurons to increase central sensitization. 
prostaglandin E2 (PGE2) and 5-HT activate voltage gated sodium 
channel type v1.8 receptors to increase pain. Prostaglandins also 
stimulate cyclic adenosine monophosphate production in sensory 
neurons and facilitate pain[18]. Histamine receptors H1, H3 and H4 are 
in the skin and are involved in pain and vasodilation[19,20].
   Several endogenous compounds facilitate the pain cycle at TRPV1, 
such as the prostaglandins prostacyclin and PGE2. Bradykinin and 
ATP bind to their own receptors which enhances pain sensation at 
TRPV1 channels[4]. Serotonin and histamine are released by mast 
cells and potentiate the activation of TRPV1[7,9]. 4-Hydroxy-2-
nonenal, hydrogen peroxide, hydrogen sulfide and other endogenous 
compounds facilitate the activation of TRPA1 channels to greatly 
increase pain[4]. 
   Drug therapy with NSAIDs can have disastrous long term effects in 
chronic pain patients. By inhibition of cyclooxygenase enzymes, the 
balance of endogenous pain causing and pain relieving compounds is 
altered. Lipoxins cause pain. Resolvins relieve pain. Prostaglandins 
cause and enhance pain. When NSAIDs are used chronically, the 
balance between these arachidonic acid derived compounds is lost. 
Pain management does not occur. Clotting and other NSAID toxicity 
problems predominate. Another problem with NSAIDs is that oral 
doses do not penetrate into the skin adequately to inhibit skin 
cyclooxygenase enzymes. Application of NSAIDs onto the skin or 
into the skin provides better pain relief[21].
3. Why is the incidence of painful conditions increasing
   Pain is an increasing clinical problem for two main reasons: the 
incidence of arthritis is increasing and patients want to be treated 
with opioids. Drug seeking behavior has become common, especially 
for hydrocodone and oxycodone. These drugs cause addiction 
and tolerance such that the dose is increased until toxicity occurs. 
Arthritis is increasing due to the increase in obesity[22]. The Centers 
for Disease Control have published statistics on their website that 
demonstrate the increase in arthritis incidence over the past 20 years 
or so. Polynesians experience 1.5 times more incidence in arthritis 
than other groups.
   Visceral fat increases during obesity, especially in adults. Visceral 
fat secretes inflammatory adipokines that damage cartilage and 
bone resulting in pain and osteoporosis[22]. Toxic lipids, such as 
ceramide and the endocannabinoids, increase in visceral fat obesity. 
Endocannabinoids increase the secretion of inflammatory adipokines 
by visceral fat. Tumor necrosis factor α, resistin, colony stimulating 
factor-1, leptin and visfatin are inflammatory adipokines involved in 
causing inflammation of the joints by stimulation of macrophages, 
T cells and neutrophils. Macrophages become osteoclasts and 
break down bone. Even chondrocytes are stimulated to break down 
cartilage. 
   Patients should be taught to alter their lifestyles in order to prevent 
arthritis. This is by far the safest and least expensive way to deal with 
arthritis. Traditional concepts such as living in balance can be taught 
to patients to help them alter their lifestyles[23]. 
4. How is cyclooxygenase-2 involved in chronic pain
   Cyclooxygenase-2 is induced in the skin and other sites 
during chronic pain[21]. Cyclooxygenase-2 is the major source 
of prostaglandins in the body. Prostaglandins bind to their own 
prostaglandin receptors to cause pain and also potentiate the 
activation of TRPV1 receptors to greatly increase pain. Inhibition 
of skin cyclooxygenase-2 is very useful in chronic pain therapy. 
However, oral administration of cyclooxygenase-2 inhibitors does 
not provide adequate therapy in the skin[21]. It is important to apply 
cyclooxygenase-2 inhibitors onto the skin to inhibit the enzyme at 
sites of pain. This allows the use of small amounts of drug and avoids 
systemic drug toxicity. The current cyclooxygenase-2 inhibitors do 
not alter the induction of the enzyme during chronic pain. Drugs 
are needed that down regulate the enzyme to provide recovery from 
chronic pain conditions.
5. Liniment for the control of pain
  A powerful pain reliever is produced from California sagebrush, 
Artemisia californica. This is a traditional medicine used by 
California Indians[24,25]. The liniment is used at painful sites on the 
skin and provides rapid pain relief that lasts for several hours. The 
liniment is used in small amounts where it is needed and avoids 
systemic penetration of large amounts of active compounds. This 
avoids systemic toxicity problems.
  The liniment contains 15 different monoterpenoids[26]. 
Monoterpenoids in general penetrate the skin easily since they are 
small, lipophilic compounds. The monoterpenoids inhibit pain at 
several TRP channels. Camphor, borneol, thujone and eucalyptol 
inhibit TRPV3[7,10,27]. Camphor also inhibits TRPA1[27]. Eucalyptol 
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inhibits pain at the TRPM8 receptor and is as potent an analgesic as 
morphine[4]. Many of the monoterpenoids in the liniment have not 
been examined to see if they are antinociceptive. It is important for 
a topical preparation to inhibit as many types of TRP channels as 
possible since the different TRP channels exist in nonoverlapping 
populations of sensory nerve terminals. Inhibition of many types 
of TRP channels may provide the maximum analgesia. It is also 
possible that a synergism may exist between the various TRP 
populations of sensory neurons such that inhibition of the outputs 
from several neurons provides more than additive pain relief. 
   Many of the monoterpenoids are anti-inflammatory agents. 
Camphene, borneol and β-pinene inhibit nitric oxide synthase and 
cyclooxygenase-2 expression through an NF-κB mechanism[28-30]. 
Not only do these compounds decrease prostaglandin production, 
they also decrease cyclooxygenase-2 activity at painful sites. This is 
a major improvement in pain management for chronic pain patients.
The liniment also contains the sesquiterpenes leucodin, 
pestalodiopsolide A, echinolactone B, tanapartholide A and 
secogorgonolide[26]. These are small, lipophilic compounds that in 
general can cross the skin. These compounds are anti-inflammatory 
agents that decrease cyclooxygenase-2 expression[31,32]. A 
diterpenoid is present in the liniment, xanthohumol disaccharide. It is 
not known if the disaccharide is cleaved to liberate free xanthohumol 
in the skin. Xanthohumol inhibits the expression of cyclooxygenase-
2[33,34]. This provides another way for the liniment to benefit chronic 
pain patients.
   The liniment also contains flavonoids and alkaloids that are anti-
inflammatory[26]. Some flavonoids and alkaloids are known to 
penetrate the skin and down regulate cyclooxygenase-2. These 
compounds add to the analgesic and anti-inflammatory effects of the 
liniment. 
   The liniment has been used in several hundred patients with 
success[26]. Patients suffering from broken bones, large abrasions 
and bruises, spinal stenosis, chronic back pain, fibromyalgia, 
osteoarthritis, rheumatoid arthritis, cancer pain, bursitis, muscle 
pain from over exertion, diabetic neuropathy and shingles have been 
successfully treated. Chronic back pain patients are advised to cut 
their doses of opioids in half every week while using the liniment. 
They are also advised to start a daily walking program that involves 
20 minutes of gentle, enjoyable walking. Walking clearly helps 
recovery in many patients. After a few weeks of therapy, many 
chronic back pain patients report recovery from pain and no further 
use of opioids.
6. Topical preparations for pain control
  Black sage, Salvia mellifera, is used as a topical preparation to 
relieve minor to moderate pain[24]. The plant is added to water or 
sea water. The preparation is placed in sun light for several hours 
to make a sun tea. Patients soak their feet in the sun tea until pain 
relief occurs, usually 20 min or so. This traditional preparation is 
used by patients suffering from arthritis pain, over exertion pain and 
cramping, headaches, bursitis, minor back pain and other pain. 
   Salvia mellifera contains 54 monoterpenoids that are slightly 
water soluble, can cross the skin and inhibit pain by inactivating 
TRP channels[35]. Monoterpenoids have octanol water partition 
coefficients ranging from 2 for alcohols to 5 for hydrocarbons[36]. 
This means they are present in water at concentrations ranging 
from a few ppm to several thousand ppm. Most drugs have octanol 
water partition coefficients in the range of -0.5 to 4.0. The plant also 
contains diterpenoids such as rosmanol and carnosic acid that are 
analgesic and anti-inflammatory agents[37]. Rosmanol is slightly 
water soluble. Carnosic acid is partly water soluble. These lipophilic 
molecules may be able to cross the skin and provide pain relief.
  Sacred Datura, Datura wrightii, is used as a topical preparation 
to relieve moderate to severe pain[24]. A sun tea made from seven 
leaves and seven flowers is used. The patient soaks the feet or hands 
in the preparation until pain relief occurs, usually about 20 min. This 
traditional preparation is used by patients suffering from abrasions 
and bruises, arthritis pain, muscle pain from over exertion, moderate 
back and neck pain, bursitis, gastrointestinal pain, joint pain, 
foot pain and other types of pain. This topical preparation is safe, 
effective and has been used by many patients. This is another topical 
preparation that delivers small amounts of active ingredient to the 
skin, disrupts the pain cycle and avoids systemic toxicity.
  The plant contains the water soluble alkaloids, hyoscyamine and 
scopolamine. Scopolamine binds to and inhibits all muscarinic 
receptors. The skin contains muscarinic receptor family (M1, M2, 
M3, M4 and M5 receptors)[38,39]. Neurons in the skin express 
M2 receptors[40]. Acetylcholine causes pain in the skin[39,41]
by binding to these receptors. Acetylcholine is released by 
autonomic nerves in the skin, endothelial cells, immune cells 
and keratinocytes[39,42]. Scopolamine crosses the skin very 
effectively and inhibits pain. Hyoscyamine and atropine do not 
efficiently cross the skin. Acetylcholine interacts with TRPV4[43]
and TRPV1 channels[44] which may increase pain. It is not known 
if scopolamine inhibits these interactions. Scopolamine potentiates 
the analgesic effects of enkephalin and morphine[45] which may 
have long term effects in pain treatment. Scopolamine is also a very 
effective antidepressant[46]. It has been known for many years that 
antidepressants are useful in chronic pain treatment. 
  Panax notoginseng, “san qi” in Chinese, root preparations are 
used as topical preparations in the treatment of pain[47]. Most of the 
bioactive components of Panax notoginseng are triterpene saponins 
called ginsenosides[48]. Apparently, ginsenosides can penetrate the 
skin after topical application[49]. The data show that ginsenoside Rg1 
inhibits TRPV1 mediated responses through an NF-kB mechanism 
that also results in cyclooxygenase-2 down regulation and less PGE2 
production[50]. Another study indicates that ginsenosides might 
directly block TRPV1 channels in sensory neurons[51]. Preparations 
of this plant have been used for centuries in many patients and are 
known to be safe.
  Resina Draconis, dragon’s blood, is a red resin from the stem of the 
tree Dracaena cochinchinensis. Flavonoids are the main chemical 
constituents of the topical preparations[52]. Steroidal saponins are 
also present[53]. This resinous medicine has anti-bacterial, anti-
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spasmodic, anti-inflammatory and analgesic activit[54]. The medicine 
can be used topically and is very popular in China.
  Some flavonoids penetrate the skin[55,56] and decrease the 
expression of nitric oxide synthase and cyclooxygenase-2, inhibit 
pain and inflammation[57-59]. Steroidal saponins may cross the skin. 
Some steroidal saponins are anti-inflammatory[60].
7. Conclusions
  In general, modern medicine seeks to use drugs that have only one 
target. For instance, the major pharmacologic activity of celecoxib 
is inhibition of cyclooxygenase-2 activity. This provides inadequate 
therapy for many pain patients, because the activity is too specific 
and because the drug does not get into the skin adequately. It is 
better to use an analgesic preparation that has many targets, such 
as inhibition of several TRP channels and down regulation of 
cyclooxygenase-2. It is better to use an analgesic preparation that 
is applied to the skin in small amounts. This provides adequate 
analgesia and avoids systemic toxicity.
  Presently, more than 100 000 people in the USA suffer from the 
toxicity of oral analgesics. Of these, 24 000 people die. Traditional 
healing teaches that topical preparations are safer and better for pain 
relief than oral preparations. Many people can be saved from death 
and suffering by simply switching to topical pain preparations.
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